Chris Vercammen

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 286 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +9

Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study

Sara Charleer, Chantal Mathieu, Frank Nobels et al. · The Journal of Clinical Endocrinology & Metabolism · 2018 · 185 citations · Full text

Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance

Katrien Benhalima, Paul Van Crombrugge, Carolien Moyson et al. · Diabetologia · 2019 · 159 citations · Full text

Insulin Resistance, Diabetes, Pregnancy Outcomes +9